APA (7th ed.) Citation

Cold, S., Sadasivam, P., Wessel, M. M., Ischyropoulou, M., Fonslet, J., Engel, T. B., . . . Kristensen, L. K. (2026). In Vivo Studies of [161Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2–Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression. Journal of Nuclear Medicine, 67(4), 542. https://doi.org/10.2967/jnumed.125.269741

Chicago Style (17th ed.) Citation

Cold, Sigrid, Pragalath Sadasivam, Mette M. Wessel, Myrto Ischyropoulou, Jesper Fonslet, Trine B. Engel, Carsten H. Nielsen, Andreas Kjaer, and Lotte K. Kristensen. "In Vivo Studies of [161Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2–Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression." Journal of Nuclear Medicine 67, no. 4 (2026): 542. https://doi.org/10.2967/jnumed.125.269741.

MLA (9th ed.) Citation

Cold, Sigrid, et al. "In Vivo Studies of [161Tb]Tb-Trastuzumab Radiopharmaceutical Therapy in Human Epidermal Growth Factor Receptor 2–Expressing Breast Tumors Show High Tumor Uptake and Tumor Growth Suppression." Journal of Nuclear Medicine, vol. 67, no. 4, 2026, p. 542, https://doi.org/10.2967/jnumed.125.269741.